Table 1.
Reports of changes in miRNA expression in laboratory models and patients with MI.
| MicroRNAs | Expression | Target | Mechanism | Model (in vitro, in vivo, human) | Tissue, blood, cell | References |
|---|---|---|---|---|---|---|
| miR-204 | Down | LC3-II | Regulated autophagy | In vivo | Tissue | (102) |
| miR-122 | Down | – | – | Human, in vivo | Tissue, blood | (103) |
| miR-519e-5p | Down | – | – | Human, in vitro | Blood, H9c2, Raw 264.7, and HUVEC cells | (104) |
| miR-150 | Down | Egr2, p2x7r | Repressed apoptosis and inflammation | In vivo, in vitro | Tissue, and HL-1, H9c2, MCEC, VSMC, and NRVC lines | (105) |
| miR-132-5p | Down | – | – | Human | Blood | (106) |
| miR-1291, miR-217, miR-455-3p, miR-566 | Down | – | – | Human | Blood | (107) |
| miR-147 | Down | HIPK2 | Inhibited inflammation and apoptosis, improved cardiac function | In vitro, in vivo | Tissue, H9c2 cells | (94) |
| miR-1, miR-92a, miR-99a, miR-223 | Down | – | – | In vitro, human | Tissue, blood | (108) |
| miR-873 | Down | RIPK1, RIPK3 | Regulated programmed necrosis | In vitro | Cardiomyocytes | (109) |
| miR-206 | Down | PTP1B | Reduced myocardial infarct size and cardiomyocytes apoptosis | In vivo, in vitro | Tissue | (110) |
| miR-378 | Down | caspase-3 | Enhanced cell viability, reduced lactate dehydrogenase release, inhibited apoptosis and necrosis | In vivo, in vitro | Tissue | (111) |
| miR-1915 | Down | – | – | Human | Blood | (112) |
| miR-126-3p, miR-26a-5p, miR-191-5p | Down | – | – | Human | Blood | (113) |
| miR-125b, miR-320b | Down | – | – | Human | Blood | (114) |
| miR-500, miR-532-3p | Down | – | – | In vivo | Tissue | (115) |
| miR-423-5p, miR-30d | Up | – | – | Human | Blood | (116) |
| miR-375 | Up | PDK-1 | Inhibited proliferation and tube formation, and enhanced apoptosis | In vitro, in vivo | Tissue, BMPACs | (117) |
| miR-208a | Up | cAMP-PKA | Influenced the cAMP-PKA signaling pathway | In vitro, in vivo | Tissue, blood | (118) |
| miR-22-5p, miR-150-3p | Up | – | – | Human | Blood | (106) |
| miR-126-3p | Up | – | – | Human | Blood | (119) |
| miR-19b-3p, miR-134-5p, miR-186-5p | Up | – | – | Human | Blood | (120) |
| miR-17-5p, miR-126-5p, miR-145-3p | Up | – | – | Human | Blood | (121) |
| miR-122-5p | Up | – | – | Human | Blood | (122) |
| miR-130 | Up | – | – | Human | Blood | (95) |
| miR-21 | Up | Smad7 | Promoted cardiac fibrosis | In vitro, in vivo | Tissue, Primary cardiac fibroblasts | (123) |
| miR-16 | Up | β2-AR | Reduced cell viability, increased apoptosis | In vitro, in vivo | Tissue, NRVCs | (124) |
| miR-125b-5p, miR-30d-5p | Up | - | - | Human | Blood | (125) |
| miR-124 | Up | - | - | Human | Blood | (126) |
| miR-144-3p | Up | PTEN | Promoted cell proliferation, migration, and collagen production | In vitro, in vivo | HCFs | (127) |
| miR-337, miR-34b | Up | – | – | In vivo, in vitro | Tissue | (128) |
| miR-424-5p | Up | – | – | Human | Blood | (129) |
| miR-205 | Up | PINK1 | – | In vivo, in vitro | Tissue, primary cardiomyocytes | (91) |
| miR-486, miR-150 | Up | – | – | Human | Blood | (130) |
| miR-320a, miR-660-5p | Up | – | – | Human | Blood | (131) |
| miR-197, miRNA-223 | Up | – | – | Human | Blood | (132) |
| miR-140 | Up | – | – | Human | Blood | (133) |
| miR-181a | Up | – | – | Human | Blood | (134) |
| miR-181c | Up | – | – | Human | Blood | (112) |
| miR-25-3p, miR-221-3p | Up | – | – | Human | Blood | (135) |
| miR-210 | Up | HIF1α | Decreased cardiac function | In vivo, human | Tissue | (136) |
| miR-486-3p | Up | – | – | Human | Blood | (137) |
| miR-3559-5p, miR-499, miR-21 | Up | – | – | In vivo | Tissue | (115) |